EASD 2023: meta analysis shows tirzepatide superiority to semaglutide Clinical Trials Arena How will Cagri Sema stack up against Tirzepatide and later Retatrutide #obesity #weightloss #T2D https: t.co ZPSQYq4RDo Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Semaglutide, Tirzepatide, Retatrutide and Cagrilintide are often lumped together, but they are not doing the same thing. : r Wegovy